Julie Anne S Billedo1, Leonard B Berkowitz2, Agnes Cha3. 1. Department of Pharmacotherapy Services, The Brooklyn Hospital Center, Brooklyn, NY, USA Julie.billedo@gmail.com. 2. Division of Infectious Diseases, The Brooklyn Hospital Center, Brooklyn, NY, USA. 3. Department of Pharmacotherapy Services, The Brooklyn Hospital Center, Brooklyn, NY, USA Department of Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA.
Abstract
PURPOSE: To compare the number of antiretroviral-related clinically significant drug-drug interactions (CSDDIs) occurring in hospitalized patients that were intervened upon before and after Antiretroviral Stewardship Program (ARVSP) expansion and to classify the interventions made to prevent errors. METHODS: A retrospective chart review of adult patients treated with antiretroviral therapy (ART) and who were hospitalized from September 2012 to February 2013. A CSDDI was defined as requiring an alternative therapy, dose adjustment, or schedule modification. Findings were compared to a prior study. RESULTS: A total of 185 admissions were included and 76 CSDDIs were identified, 19 (25%) occurred after ART approval. The percentages of CSDDIs that occurred after ART approval and were intervened upon before and after ARVSP expansion were 43% and 95%, respectively (P<.001). An additional 80 other interventions were made by the ARVSP. CONCLUSION: An ARVSP is critical in the prevention of CSDDIs and errors to improve safety in HIV-infected patients.
PURPOSE: To compare the number of antiretroviral-related clinically significant drug-drug interactions (CSDDIs) occurring in hospitalized patients that were intervened upon before and after Antiretroviral Stewardship Program (ARVSP) expansion and to classify the interventions made to prevent errors. METHODS: A retrospective chart review of adult patients treated with antiretroviral therapy (ART) and who were hospitalized from September 2012 to February 2013. A CSDDI was defined as requiring an alternative therapy, dose adjustment, or schedule modification. Findings were compared to a prior study. RESULTS: A total of 185 admissions were included and 76 CSDDIs were identified, 19 (25%) occurred after ART approval. The percentages of CSDDIs that occurred after ART approval and were intervened upon before and after ARVSP expansion were 43% and 95%, respectively (P<.001). An additional 80 other interventions were made by the ARVSP. CONCLUSION: An ARVSP is critical in the prevention of CSDDIs and errors to improve safety in HIV-infectedpatients.
Authors: Marisa B Brizzi; Rodrigo M Burgos; Thomas D Chiampas; Sarah M Michienzi; Renata Smith; Paa Kwesi Yanful; Melissa E Badowski Journal: Open Forum Infect Dis Date: 2020-08-24 Impact factor: 3.835
Authors: Ashley M DePuy; Rafik Samuel; Kerry M Mohrien; Elijah B Clayton; David E Koren Journal: Open Forum Infect Dis Date: 2019-06-24 Impact factor: 3.835
Authors: David E Koren; Kimberly K Scarsi; Eric K Farmer; Agnes Cha; Jessica L Adams; Neha Sheth Pandit; Jennifer Chang; James Scott; W David Hardy Journal: Clin Infect Dis Date: 2020-05-23 Impact factor: 9.079